Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)Ibrahim Yakoub‐Agha, Nicolaus Kröger|Haematologica|2019Cited by 353
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Théo de Witte, Simona Iacobelli et al.|Journal of Clinical Oncology|2017Cited by 248
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donorsDietger Niederwieser, Wael Saber, Kristjan Paulson et al.|Haematologica|2021Cited by 236
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow TransplantationMohamad Mohty, Rafael F. Duarte, Kai Hübel et al.|Bone Marrow Transplantation|2014Cited by 192
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosisFelix Fischbach, Nicolaus Kröger, Johanna Richter et al.|Med|2024Cited by 161